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Schizophrenia is a severe mental disorder, with a highly complex and heterogenous
clinical presentation. Our current perspectives posit that the pathogenic mechanisms
of this illness lie in complex arrays of gene × environment interactions. Furthermore,
several findings indicate that males have a higher susceptibility for schizophrenia, with
earlier age of onset and overall poorer clinical prognosis. Based on these premises,
several authors have recently begun exploring the possibility that the greater schizophrenia
vulnerability in males may reflect specific gene × sex (G×S) interactions. Our knowledge
on such G×S interactions in schizophrenia is still rudimentary; nevertheless, the bulk
of preclinical evidence suggests that the molecular mechanisms for such interactions
are likely contributed by the neurobiological effects of sex steroids on dopamine
(DA) neurotransmission. Accordingly, several recent studies suggest a gender-specific
association of certain DAergic genes with schizophrenia. These G×S interactions have
been particularly documented for catechol-O-methyltransferase (COMT) and monoamine
oxidase (MAO), the main enzymes catalyzing DA metabolism. In the present review, we
will outline the current evidence on the interactions of DA-related genes and sex-related
factors, and discuss the potential molecular substrates that may mediate their cooperative
actions in schizophrenia pathogenesis.
Keywords: schizophrenia, dopamine, catecholamine-O-methyltransferase (COMT), monoamine oxidase (MAO),
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INTRODUCTION
Schizophrenia is a chronic and severe neurodevelopmental dis-
order, characterized by a highly complex and heterogeneous set
of perceptual, cognitive and emotional deficits (Breier, 1999;
Rowley et al., 2001). According to the current diagnostic criteria,
the pathognomonic manifestations in schizophrenia are clustered
into three groups of symptoms: (1) positive symptoms, which
encompass hallucinations and delusions; (2) negative symptoms,
including flat affect, alogia, anhedonia and social deficits; and (3)
cognitive symptoms, which reflect impairments of attention, mem-
ory, perception and thought. Converging evidence has revealed
that the primary deficits in schizophrenia are likely mediated
by dopamine (DA), in cooperation with other key neurotrans-
mitters, such as glutamate, γ-aminobutyric acid (GABA) and
serotonin. Nevertheless, the quest to understand the pathogenic
mechanisms of schizophrenia has not yet led to a conclusive
theory, and its pathophysiology remains frustratingly elusive.
A wealth of genetic data has identified a number of vulnera-
bility factors that are not inherently pathological, but predispose
an individual to develop schizophrenia in the presence of critical
environment determinants. These findings have prompted a shift
in the conceptual framework of schizophrenia, and underscored
the importance of gene-environment (G×E) interactions in this
disease (Van Os and Murray, 2008; Van Os et al., 2008, 2010; Van
Os and Rutten, 2009).
Multiple lines of evidence have also highlighted that sex-
related factors play a potentially important role in shaping the
clinical trajectory of schizophrenia. Indeed, males have a higher
risk for schizophrenia than females, with earlier age of onset and
greater severity of negative and cognitive symptoms (Markham,
2012). Based on these premises, it is possible to theorize the exis-
tence of specific gene × sex (G×S) interactions that may also
contribute to schizophrenia pathogenesis.
Numerous preclinical studies support that the DAergic system
is one of the key mediators of sex differences in schizophre-
nia (Bay-Richter et al., 2009; Arime et al., 2012; for a detailed
presentation of this issue, see Sanchez et al., 2010); accord-
ingly, genetic investigations point to a clear involvement of
the key metabolic enzymes of DA, catechol-O-methyltransferase
(COMT) and monoamine oxidase (MAO), in the underpinnings
of G×S interactions in schizophrenia. In the present review, we
will discuss how the emerging evidence on the genes encoding
these enzymes and their interactions with sex-related factors may
provide fundamental clues to unravel the essence of the biological
bases of schizophrenia.
THE ROLE OF DA IN THE PATHOPHYSIOLOGY OF
SCHIZOPHRENIA
The role of dopamine in the pathogenesis of schizophrenia was
originally postulated following the discovery that D2 dopamine
receptor antagonism was a fundamental pharmacological requi-
site of antipsychotic drugs, and that the therapeutic efficacy of
these agents was correlated with their inhibitory potency (Seeman
and Lee, 1975; Creese et al., 1976). While several studies support
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the concept that stimulation of D2 receptors in subcortical areas
(and particularly striatum and nucleus accumbens) results in
psychotic manifestations, other lines of evidence strongly sug-
gest that negative and cognitive symptoms (which are generally
not affected by D2 receptor antagonists) may be underpinned
by the insufficient activation of D1-like receptors in the pre-
frontal cortex (PFC) (Goldman-Rakic and Selemon, 1997). These
findings have led to the view that schizophrenia may be under-
pinned by mesolimbic hyperactivity and mesocortical hypoac-
tivity (Weinberger, 1987; Davis et al., 1991). Although studies
in the last two decades have documented the fundamental roles
of other neurotransmitters in schizophrenia, particularly gluta-
mate and GABA (Benes and Berretta, 2001; Tsai and Coyle, 2002),
the DAergic hypothesis still affords the best-validated theoretical
framework for this disorder. Recent imaging and post-mortem
studies have lead to a refinement of this hypothesis, indicating
that the dysregulations of DA neurotransmission in cortex and
elevations in presynaptic DA content in the striatum may be the
main biological signatures of psychotic disorders (Howes and
Kapur, 2009; Fusar-Poli et al., 2011; Howes et al., 2011, 2012,
2013; Allen et al., 2012; Egerton et al., 2013; Stokes et al., 2013;
Lataster et al., 2014; see Kuepper et al., 2012 and Smieskova et al.,
2013 for more thorough reviews on dopaminergic dysfunctions
in brain imaging studies in schizophrenia). The increase in presy-
naptic striatal DA may disrupt informational salience and help
contribute to other schizophrenia symptoms (Rosier et al., 2013;
Winton-Brown et al., 2014).
The bulk of the evidence suggests that the DAergic deficits in
schizophrenia are underpinned by functional, rather than con-
stitutive, abnormalities. Indeed, the majority of studies on post-
mortem tissues have failed to identify consistent alterations in
the expression of DAergic targets (Harrison, 2000). Accordingly,
multiple large-scale genetic analyses have found no robust associ-
ation for DAergic genes and schizophrenia (Hoogendoorn et al.,
2005; Alvarez et al., 2010), and instead point to a predominant
involvement of glutamatergic targets (Collier and Li, 2003). In
contrast with this evidence, the notion of functional dysregula-
tion of DAergic circuits in schizophrenia is strongly supported
by neuroimaging findings, which point to multiple patterns of
dysconnectivity between intracortical and subcortical networks
(Laruelle, 2003). These dynamic alterations of DAergic neuro-
transmission are thought to play a key role in the adaptive and
neurodevelopmental processes of this system, which are par-
ticularly active throughout childhood and adolescence (Teicher
et al., 1995; Spear, 2000). These developmental periods may be
especially critical for the interactions of DAergic genes with envi-
ronmental and sex-related vulnerability factors in schizophrenia.
In fact, preclinical experiments have shown that sex hormones
have a profound influence on the development of the DAergic
system throughout early developmental stages (Anderson et al.,
2005).
To establish a conceptual framework for the role of DA in
schizophrenia, it is necessary to consider that one of the fun-
damental functions of this system is the extraction of salient
information from the environment, through the stimulation of
output neurons of cortical and striatal regions integrated within
cortico-striato-thalamo-cortical (CSTC) circuits. In particular,
the role of mesocorticolimbic DAergic neurons is consistently
influenced by the action of glutamatergic and GABAergic cells,
which surround and interface with the somata in the ventral
tegmental area, as well as the axons and presynaptic boutons in
the efferent areas (nucleus accumbens, striatum and PFC). In
line with the role of DAergic pathways as neural mediators of
informational salience, both the adaptive plasticity andmodalities
of neurotransmitter release by these neurons are finely regu-
lated by multiple factors; changes in these variables, particularly
if occurring during developmental periods, may therefore have
long-standing implications on the integrity and coherence of
the perceptual process. The modulatory role of DA on process-
ing informational salience is extremely critical during adolescent
stages, in which the DAergic system alters cortical innervation and
undergoes synaptic maturation and pruning of its glutamatergic
and GABAergic connections (Andersen, 2003; O’Donnell, 2010;
Burke and Miczek, 2013; Penzes et al., 2013).
The natural corollary of these premises is that the DAergic
system may be directly involved in G×S interactions during
postnatal development, while prenatal and inborn elements of
predisposition may be more directly related to the glutamatergic
system (which in turn governs DAergic function through direct
and indirect dynamic interactions). This idea is in line with the
“multiple hits” hypothesis for the pathogenesis of schizophrenia,
which postulates that the disorder may result from the progres-
sive accumulation of deficits from prenatal to juvenile stages, due
to different, yet concurring, causes. In the next sections, we will
present an overview of the role of sex hormones on schizophrenia,
followed by a detailed discussion on the available evidence on the
G×S interactions involving DAergic genes.
THE ROLE OF SEX FACTORS IN SCHIZOPHRENIA
GENDER DIFFERENCES IN SCHIZOPHRENIA
The existence of gender differences in schizophrenia has been rec-
ognized since its first nosographic description by Kraepelin. The
best-characterized difference concerns arguably the earlier age of
onset in male patients, which typically ranges from 15 to 24 years.
In comparison, females exhibit their first overt clinical manifes-
tations between 20 and 29 years, with an average difference of
3–5 years from males (Angermeyer and Kuhn, 1988). It is widely
assumed that this divergence in age reflects different develop-
mental trajectories in the DAergic system throughout adolescence
across both genders.
A comprehensive and systematic analysis of sex differences
in schizophrenia is a complicated undertaking, in view of sev-
eral methodological issues that may generate spurious results,
such as recruitment bias, differentmetabolic responses to antipsy-
chotic drugs and gender diversity in social adjustment with
respect to psychiatric disorders (Markham, 2012). The awareness
of these issues, and the numerous discrepancies in the litera-
ture have led several authors to cast a skeptical eye on other
potential sex differences in schizophrenia, such as prevalence
and symptomatic presentation (Häfner, 2002; Jablensky, 2003).
Nevertheless, more recent studies, performed with more accurate
and tighter controls, have actually found that the gender dif-
ferences in schizophrenia may encompass several aspects of this
disorder, including: (1) a higher risk of schizophrenia in males
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(∼40%) (Markham, 2012); (2) poorer premorbid adjustment in
males; (3) a greater severity in clinical course in males, charac-
terized by higher frequency and intensity of negative symptoms,
as well as more rapid cognitive deterioration and greater predis-
position to relapse (Larsen et al., 1996; Markham, 2012). Current
studies investigating the role of sex differences in neuropsychi-
atric disorders have also highlighted the potential impact of stress
and hormonal influences on epigenetic phenomena, which may
result in enduring behavioral changes across subsequent genera-
tions (see Goel and Bale, 2009; McCarthy et al., 2009; Bale, 2011;
McCarthy and Nugent, 2013).
ROLE OF ESTROGENS IN SCHIZOPHRENIA
The prevalent line of interpretation of this sex-related dispro-
portion lies in the neuroprotective role of estrogens in women
(Seeman, 1996). Indeed, women display greater severity of their
psychotic symptoms in conditions associated with lower con-
centrations of β-estradiol, the main estrogen hormone, such
as fluctuations within the menstrual cycle (Bergemann et al.,
2007; Rubin et al., 2010), and menopause (Häfner et al., 1993).
Furthermore, plasma β-estradiol levels are reduced in schizophre-
nia female patients across all phases of the menstrual cycle
(Riecher-Rossler et al., 1994), and the age of disease onset in
women is inversely related to the age of puberty (Cohen et al.,
1999). Accordingly, several clinical trials have shown that addi-
tive treatment with estradiol substitutes improves and accelerates
the therapeutic response of patients (Kulkarni et al., 1996, 2002;
Akhondzadeh et al., 2003; Kulkarni et al., 2008). A number of
clinical studies have also shown associations between estrogen
receptor polymorphic variants in psychotic-related phenomena
(Weickert et al., 2008; Min et al., 2012; Wang et al., 2013). In
general, it appears that the sex factors do not induce specific qual-
itative differences in symptoms, but rather dampen the severity
or delay the onset of the same manifestations. The biochemical
nature of the neuroprotective effects of estrogens has not been
fully qualified yet, but a number of studies point to a direct impli-
cation of the DAergic system (Sumner and Fink, 1993; Fink et al.,
1998), in addition to glutamate and GABA. In general, the rela-
tions between estrogens andDA are supported by a host of clinical
and preclinical evidence (for a thorough and detailed presentation
of this issue, see Sanchez et al., 2010).
ROLE OF ANDROGENS IN SCHIZOPHRENIA
The involvement of sex steroids in schizophrenia is not likely
limited to estrogens, but may also include androgen hormones.
These steroids appear to exert a multifaceted influence on the
neurobiological substrates of schizophrenia; in particular, the
complexity of this role stems from the fact that testosterone,
the main gonadal androgen, is also converted into β-estradiol
via aromatization. Men with schizophrenia tend to exhibit lower
levels of testosterone, and testosterone levels are inversely cor-
related with the severity of negative symptoms (Akhondzadeh
et al., 2006; Ko et al., 2007). Furthermore, this hormone has
been shown to exert therapeutic properties for negative symp-
toms in schizophrenia (Ko et al., 2008). In contrast, the role
of other androgens in schizophrenia is less clear. For exam-
ple, schizophrenia patients exhibit high levels of the adrenal
androgens dehydroepiandrosterone (DHEA) and androstene-
dione (Ritsner and Strous, 2010); in addition, DHEA has been
found to attenuate the extrapyramidal symptoms induced by
antipsychotic drugs (Ritsner et al., 2010).
In general, it is possible that androgenic metabolites of testos-
terone may facilitate the development of schizophrenia-related
symptoms. The conversion of testosterone and androstenedione
into their androgenic metabolites dihydrotestosterone (DHT)
and androstanedione, respectively, is mediated by 5α-reductase
(Paba et al., 2011). Notably, this process competes with the arom-
atization of the same substrates to β-estradiol and β-estrone. In
males, 5α-reductase activity is enhanced during puberty; thus,
it is possible that the increased rate of conversion of testos-
terone and androstenedione into their 5α-reduced androgenic
metabolites (instead of estrogens) may contribute to the greater
schizophrenia vulnerability and earlier age of onset in males. Our
group has tested this intriguing hypothesis in rodent models of
schizophrenia; our results indicate that inhibition of 5α-reductase
leads to marked anti-DAergic actions on endophenotypes rele-
vant to schizophrenia, such as sensorimotor gating deficits and
stereotyped behavior (Bortolato et al., 2008a; Paba et al., 2011;
Devoto et al., 2012; Frau et al., 2013). In addition, we recently
found that inhibition of another key androgen-synthetic enzyme,
CYP17A1, elicits similar, albeit less potent, anti-DAergic effects in
the same schizophrenia-related behavioral paradigms (Frau et al.,
2014). Collectively, these findings highlight that, in addition to
testosterone, other androgens may have a role in the pathogenesis
of schizophrenia-related features, through the mediation of DA
neurotransmission (for a more detailed description of this issue
and its potential therapeutic implications, see Paba et al., 2011).
THE ROLE OF DAergic GENES IN G×S INTERACTIONS IN
SCHIZOPHRENIA
COMT
COMT catalyzes the methylation of the 3O group of cat-
echolamines. The methyl group is donated by S-adenosyl-
methionine (SAM), and DA is directly converted by COMT
into metanephrine. Other catechol-containing structures are sub-
strates of COMT, including norepinephrine, epinephrine and the
DA precursor l-DOPA.
COMT has a soluble form (S-COMT) and a membrane-
bound form (MB-COMT), both of which are encoded by the
same gene (Lundstrom et al., 1991), located on chromosome
22q11.2. COMT expression is controlled by two promoters in the
third exon of the gene (Salminen et al., 1990; Lundstrom et al.,
1991). The P1 promoter regulates the expression of a shorter
transcript, which can code for S-COMT only (Tenhunen et al.,
1993), whereas the more distally located P2 promoter can encode
both transcripts. S-COMT is generally dominant in most tissues,
with the only exception being in the human brain, where 70%
is MB-COMT, and 30% is S-COMT. In the brain, S-COMT is
mostly found in the glia and is not likely to serve a primary func-
tion in DA metabolism (Rivett et al., 1983; Naudon et al., 1992);
conversely, MB-COMT is abundantly localized in postsynaptic
terminals of neurons and in perisynaptic locations (Bertocci et al.,
1991; Lundstrom et al., 1991; Schott et al., 2010). This form is
likely to play a key role in DA degradation, particularly in regions
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with low DA transporter (DAT) expression, such as the PFC,
or, alternatively, in conditions of DAT inhibition (Karoum et al.,
1994; Sesack et al., 1998; Huotari et al., 1999; Matsumoto et al.,
2003).
Notably, the effect of COMT on DA metabolism may be par-
ticularly dominant in males; indeed, only COMT knockout males
exhibit a significant (3-fold) increase in DA levels in the PFC
(Gogos et al., 1998). MB-COMT is generally localized intracel-
lularly, but not in the cell membrane (Ulmanen et al., 1997).
This distribution implies that its function in DA metabolism is
secondary to DA uptake in the postsynaptic terminal (Figure 1),
which may be served by either the organic cation transporter 3
(OCT3; SLC22A3) or the plasma membrane monoamine trans-
porter (PMAT; SLC29A4) located in the postsynaptic neuron or
glia. PMAT is highly expressed in the forebrain (Engel et al., 2004;
Dahlin et al., 2007), including brain regions with sparse DAT
expression.
The perisynaptic location of COMT suggests that this enzyme
may be important for volume transmission of DA, which plays an
important role in the PFC (Paspalas and Goldman-Rakic, 2004).
Given the relevance of volume neurotransmission in the PFC
for the acquisition of certain informational aspects, such as the
perception of salience and the dynamic regulation of signal-to-
noise ratio, alterations in COMT activity may result in cognitive
changes, particularly with respect to PFC-mediated functions. In
addition, COMT may be a crucial element in differentiating the
temporal patterns of tonic and phasic DA action (Bilder et al.,
2004).
A host of studies have proposed the COMT gene as a poten-
tial candidate for psychosis and related phenomena (Egan et al.,
2001; Williams et al., 2007). In particular, numerous investi-
gations have focused on rs4680, one of the best-characterized
single-nucleotide polymorphisms of the COMT gene, resulting in
the substitution of a valine (Val) for a methionine (Met) residue
at position 108 of S-COMT and 158 of MB-COMT (Val-Met)
(Lachman et al., 1996; Harris et al., 2005; Wahlstrom et al., 2007).
The Val-allele confers a higher intrinsic COMT activity than the
Met-allele (Männistö and Kaakkola, 1999), leading to an overall
reduction in DA levels in the PFC. Indeed, COMT serves as the
primary enzyme for DA metabolism in this region (Egan et al.,
2001; Schott et al., 2006; Tan et al., 2007; Diaz-Asper et al., 2008).
Accordingly, individuals harboring the Val allele exhibit low DA
levels predominantly in the PFC, which may result in a region-
specific dysregulation of DA receptors (and particularly D1, the
most abundant DA receptor in the cortex). Conversely, striatal
DA levels and D2 receptor availability appear to be unaffected
by alterations in COMT activity (Yavich et al., 2007; Hirvonen
et al., 2010). Moreover, Val-allele carriers have been associated
with impaired physiological responses across several functional
domains, including cognitive flexibility, working memory, atten-
tional control and emotional resilience (Malhotra et al., 2002;
Goldberg et al., 2003; Blasi et al., 2005; Smolka et al., 2005).
The role of COMT in schizophrenia has been extensively stud-
ied, yet results have unequivocally shown that neither genetic
variants nor the catalytic activity of the enzyme have great intrin-
sic influence on schizophrenia risk (Chen et al., 1996; Daniels
et al., 1996; Riley et al., 1996; Wei et al., 1996; Karayiorgou et al.,
1998; Wei and Hemmings, 1999; De Chaldee et al., 2001; Semwal
et al., 2001; Strous et al., 2006). Nevertheless, multiple lines of
evidence indicate that high-activity COMT variants is robustly
FIGURE 1 | Schematic diagram of DA synaptic metabolism. Abbrevations 3-MT, 3-Methoxytyramine; COMT, Catechol-o-methyltransferase; DA, DA; DAT, DA
reuptake transporter; DOPAC, 3,4-Dihydroxyphenylacetic acid; HVA, Homovanillic acid; MAO, Monoamine oxidase.
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associated with a greater severity of negative and cognitive symp-
toms in schizophrenia patients, as well as specific endophenotypic
impairments related to functional deficits of the PFC (Egan
et al., 2001; Herken and Erdal, 2001; Weinberger et al., 2001;
Weinberger, 2002). Specifically, the Val allele has been associated
with poorer performance in schizophrenia patients across sev-
eral neuropsychological tests for executive functioning (Goldberg
et al., 2003; Nolan et al., 2004; Ohnishi et al., 2006; Diaz-Asper
et al., 2008; Opgen-Rhein et al., 2008; Ira et al., 2013), as well
as sensorimotor gating deficits in comparison to carriers of the
Met allele (Quednow et al., 2010). Individuals harboring the Val
variant also exhibit greater prefrontal noise, corresponding to the
electromagnetic activity in the region (Winterer et al., 2006). In
contrast, multiple studies have ascertained that the Met variant
is associated with a slightly lower schizophrenia risk, as well as
less severity of attentional, cognitive and information-processing
deficits (Egan et al., 2001; Bilder et al., 2002; Bray et al., 2003;
Gallinat et al., 2003; Tunbridge et al., 2006; Ehlis et al., 2007; Lu
et al., 2007).
Although the aforementioned studies indicate that the Val
variant confers at best a very modest enhancement of schizophre-
nia risk, recent investigations suggest that the interaction of this
haplotype with other genetic or environmental vulnerability fac-
tors may lead to schizophrenia (Schenkel et al., 2005; Stefanis
et al., 2007; Collip et al., 2011; Pelayo-Teran et al., 2012). In par-
ticular, the interaction of the Val variant with cannabis abuse
in adolescence has been shown to increase schizophrenia risk
(Caspi et al., 2005; Henquet et al., 2006; Estrada et al., 2011),
but the neurobiological bases of this interaction remain poorly
understood.
While most of the research on COMT genotypes and
schizophrenia has been focused on the impairments associated
with the Val variant, emerging lines of evidence have also pointed
to the possibility that theMet-variant may predispose schizophre-
nia patients to aggression and violence (Strous et al., 1997;
Lachman et al., 1998; Nolan et al., 2000; Liou et al., 2001; Han
et al., 2004, 2006; Kim et al., 2008; Tosato et al., 2011; Bhakta et al.,
2012; Singh et al., 2012). Interestingly, this predisposition appears
to be specific for males, pointing to a potential G×S interaction
(Nolan et al., 2000; Soyka, 2011; Singh et al., 2012).
A summary of the main studies that have identified G×S inter-
actions concerning COMT polymorphisms is reported in Table 1.
Although these data should still be regarded as preliminary, sev-
eral studies suggest that male patients with high-activity COMT
may have greater severity of endophenotypes associated with
prefrontal deficits in schizophrenia, such as eye movement distur-
bances (Rybakowski et al., 2002) prefrontal noise (Winterer et al.,
2006) and schizotypal traits (Ma et al., 2007). Similarly, Hoenicka
et al. (2010) found that the effects of the Val158Met polymor-
phism on schizophrenia vulnerability are more directly related to
male patients, possibly through an epistatic interaction with D1
receptor (Hoenicka et al., 2010) (see below). Other studies indi-
cate that only female carriers of the Val/Met alleles exhibit high
propensity to engage in risky behaviors (Amstadter et al., 2012)
and alterations in emotional processing (Domschke et al., 2012).
COMT activity has been reported to be higher in males than
females (Boudikova et al., 1990). This gender difference may
reflect the ability of testosterone and DHT to increase COMT
expression (Purves-Tyson et al., 2012). Alternatively, estrogens
have been found to reduce the transcription and expression of
COMT (Männistö et al., 1992; Xie et al., 1999). An additional
mechanism that may predict a lower COMT activity in females
may be afforded by the function of catecholestrogens. These 2-
and 4-hydroxylatedmetabolites of β-estradiol (Ball and Knuppen,
1980; Zhu and Conney, 1998) compete with DA for COMT-
mediated metabolism, and may act as inhibitors of the enzyme
at high concentrations. Accordingly, catecholestrogens have been
shown to modulate the turnover of catecholamines (Parvizi and
Wuttke, 1983). While the specific role of catecholestrogens on
G×S interactions of COMT in schizophrenia remains to be inves-
tigated, the reduction of COMT activity in females may explain
the lower susceptibility of this gender for the phenotypic effects
of the Val variant on PFC function. At the same time, this mech-
anism could also account for the higher proclivity of female
carriers of the Met allele to engage in risky behaviors (Amstadter
et al., 2012).
A number of preclinical studies have found sex-specific neu-
rochemical and behavioral differences associated with COMT
(Gogos et al., 1998). In particular, heterozygous male COMT-
deficient mice exhibit impaired object recognition (Babovic et al.,
2008). Conversely, COMT overexpression was found to be asso-
ciated with blunted stress responsiveness, as well as impairments
in working memory and attentional set-shifting (Papaleo et al.,
2008). These data are in agreement with evidence showing that
COMT alterations may negatively impact prefrontal functions in
both humans and rodents (Papaleo et al., 2012). In a recent study,
Risbrough and colleagues found that male mice carrying the
COMT158Val-variant exhibit marked reductions in spatial work-
ing memory and disruptions in sensorimotor gating; conversely.
female mice carrying the COMT158Met-variant displayed alter-
ations in fear-related behavioral responses (Risbrough et al.,
2014). Collectively, these preclinical findings further support the
role of sex-specific influences of COMT genetic variations on
prefrontal DAergic systems.
MAO A AND B
MAO A and B are mitochondrial-bound enzymes (Greenawalt
and Schnaitman, 1970) differing by substrate affinity. MAO A
has high affinity for serotonin and norepinephrine, while MAO
B metabolizes the trace amine phenylethylamine. DA can be
degraded by both isoforms; however, the primary enzyme dif-
fers across species. In humans and primates, MAO B is the major
metabolic enzyme of DA, whereas MAO A serves this role in
rodents (Garrick and Murphy, 1980; Cases et al., 1995; Fornai
et al., 1999). The metabolism of DA mediated by MAOs occurs,
for the most part, in the presynaptic terminal, following reup-
take by the DAT. The difference between MAO A andMAO B also
concerns their anatomical localization. MAO A is localized in cat-
echolaminergic neurons (and in particular in the locus coeruleus,
nucleus accumbens, hypothalamus and mammillary complex),
whereas MAO B is found in serotonergic neurons, as well as his-
taminergic cells and astrocytes (Westlund et al., 1988; Saura et al.,
1994; Luque et al., 1995, 1996; Jahng et al., 1997; Bortolato et al.,
2008b).
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Table 1 | List of major studies documenting an interaction between COMT polymorphic variants and sex in schizophrenia and related
symptoms.
Study aim Polymorphisms (SNP
if applicable)
Total subjects Male: female
ratio
Finding References
Clinical response of risperidone
in Chinese schizophrenic
patients
10 SNPs rs9606186 130 45:85 patients Increased efficacy of
risperidone efficiency in
males
Zhao et al., 2012
Gender effects of COMT
polymorphisms on cognitive
function in children
Val/Val 8707 children Numbers not
indicated
Val/Val genotype scored
lower on selective attention
and executive functioning
than Met/Met in males
Barnett et al.,
2007
COMT genetic polymorphisms
association with Chinese
schizophrenic patients
rs740603 and rs4818 604 (284
patients and 320
controls)
203:81 patients
140:180 controls
Significant association with
negative symptoms in
females
Li et al., 2012
COMT genotypes in
schizophrenia risk
rs165774; rs174675;
rs4646316; rs4680;
rs6267; rs737866;
rs740603
410 (160
patients and 250
controls)
138:22 patients
148:102 controls
Significant genotype
assocation with
schizophrenia in males
Voisey et al.,
2012
COMT polymorphisms
association with tardive
dyskinesia
rs737865; rs6269; rs
4633; rs4818; rs4680;
rs165599
226 (90 positive
for Tardive
dyskinesia)
140:73 patients Higher association of
antipsychotic-induced
tardive dyskinesia
occurance in males
Zai et al., 2010
Role of D1 dopamine receptor
polymorphisms and its
interaction with COMT
genotype in schizophrenia
Val/Val 701 (337
patients and 364
controls)
226:111 patients
171:193 controls
D1 dopamine receptor
polymorphisms and COMT
Val/Val genotype associated
with schizophrenia in males
Hoenicka et al.,
2010
Impact of COMT genotype on
sensorimotor gating in healthy
colunteers
Val/Val and Val/Met 107 healthy
controls
54:53 controls Serotonin 2A receptor
polymorphisms and males
with COMT Val/Val or
Val/Met have sensorimotor
gating deficits
Quednow et al.,
2009
Association between
schizotypal traits and COMT in
a healthy Chinese population
Val/Met 465 healthy
controls
231:234 controls Met alleles showed
increased schizotypal
personality questionnaire
scores in males
Ma et al., 2007
Association of prefrontal
electrophysiologic “noise” and
COMT genotype in
schizophrenia patients
Val/Val 282 (83 patients;
87 siblings; 112
controls)
65:18 patients
31:56 siblings
66:46 controls
Val/Val-allele males exhibit
higher prefrontal “noise”
Winterer et al.,
2006
Role of COMT genotype in
schizophrenia on performance
on wisconsin card sorting test
Val/Val 124 patients 60:64 patients Male Val/Val alleles
displayed best (lowest)
scores in Wisconsin card
sorting test; Female Val/Val
carriers had worst (highest)
scores
Rybakowski
et al., 2006
COMT genotype on psychosis
in Alzheimer’s disease
Val/Met 373 patients 130:243 patients Female Val/Met carriers
with Alzheimer’s disease
had a higher risk of
psychosis
Sweet et al.,
2005
(Continued)
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Table 1 | Continued
Study aim Polymorphisms (SNP
if applicable)
Total subjects Male: female
ratio
Finding References
Role of COMT in schizophrenia
vulnerability in Arabic
population
Val/Val 332 (255
patients and 77
controls)
161:94 patients
31:53 controls
Female Va/Val carriers
display higher risk for
schizophrenia, while male
Val/Met carriers have higher
risk
Kremer et al.,
2003
COMT genotype on eye
movement disturbances in
schizophrenia patients
Met/Met 177 (117 patients
and 60 controls)
74:43 patients
29:31 controls
Male schizophrenia patients
with Met/Met genotype
had lower oculomotor
disturbances
Rybakowski
et al., 2002
Role of COMT in homicidal
behavior in schizophrenia
patients
Met/Met 507: 30 violent
patients; 62
nonviolent
patients; 415
controls
28:2 violent
patients 30:32
nonviolent
patients 159:256
controls
Higher Met/Met male
carriers in violent
schizophrenic patients
Kotler et al.,
1999
Role of COMT in schizophrenia
vulnerability in Jewish
population
12 SNPs: Val/Val
rs165599 and Val/Val
rs165599-rs165688
12906 (2188
patients and
10718 controls)
1383:775
patients
7947:2771
controls
rs165599Val/Val and
rs165599-rs165688 higher
in female schizophrenia
patients
Shifman et al.,
2002
Role of COMT genotype in
cognition in children
Haplotype (rs6269;
rs4633 and 4s4818)
rs2075507 (previously
rs2097603); rs6269;
rs4818; rs4680;
rs165599
8173 children 4211:3962
children
ValB/ValB (lowest COMT
activity) haplotype with
highest Verbal IQ; Val/Val in
rs165599 show lower
working memory in males
Barnett et al.,
2009
Several studies have documented that MAOA gene polymor-
phisms are associated with different psychiatric disturbances
(Ozelius et al., 1988; Black et al., 1991; Hotamisligil and
Breakefield, 1991; Hinds et al., 1992; Shih and Thompson, 1999).
Most of the genetic studies on MAOA have focused on a vari-
able number tandem repeat (VNTR) polymorphism, which is
located 1.2-kilobase upstream of the transcription initiation site
and has been associated with changes in gene expression (Sabol
et al., 1998). Of the six different allelic variants characterized in
humans, the most common display 3 repeats (3R) and 4 repeats
(4R) (Sabol et al., 1998; Deckert et al., 1999; Jonsson et al.,
2000). The 3R variant has been associated with behavioral fea-
tures linked to low MAO A activity, such as impulsive aggression
and antisocial personality (Oreland et al., 2007; Buckholtz and
Meyer-Lindenberg, 2008). In contrast, the 4R variant has been
associated with higher MAOA gene transcription and enzyme
activity (Sabol et al., 1998; Denney et al., 1999). Neuroimaging
imaging studies have found a link between the VNTR variants of
MAOA promoter and structural and functional differences in the
PFC (Meyer-Lindenberg et al., 2006).
In general, the majority of genetic studies have failed to find
a straightforward association between MAOA and schizophrenia
(Coron et al., 1996; Sasaki et al., 1998; Syagailo et al., 2001; Norton
et al., 2002; Iwata et al., 2003; Li and He, 2008; Wei et al., 2011).
Nevertheless, other analyses found preliminary results in support
of a sex-specific effect of MAOA with respect to schizophrenia
diagnosis or select symptomatic aspects of the disorder (Jonsson
et al., 2003; Qiu et al., 2009; Camarena et al., 2012; Sun et al.,
2012b).
A summary of the main findings on potential G×S interac-
tions involving the MAOA gene is reported in Table 2. Although
the evidence on sex-dependent effects of MAOA is still pre-
liminary and inconclusive, it was recently reported that male
schizophrenia patients exhibit abnormal patterns of methyla-
tion of the MAOA promoter, pointing to the possibility that the
effect of sex may be directly dependent on epigenetic alterations
(Chen et al., 2012). In addition to the evidence on schizophre-
nia, several findings have documented that genetic variations of
MAOA may play a central role in neuropsychiatric disorders in
a sex-dependent fashion. This concept is best highlighted by the
elegant study conducted by Caspi and colleagues, showing that
males, but not females, harboring low MAO A activity poly-
morphic variants and subjected to early childhood maltreatment
exhibit a significantly higher vulnerability to develop antisocial
and aggressive behaviors in adulthood (Caspi et al., 2002; Foley
et al., 2004; Kim-Cohen et al., 2006). Indeed, subsequent stud-
ies have found that testosterone levels in the cerebral spinal fluid
paralleled aggressive responses in carriers of the lowMAOA activ-
ity polymorphism (Sjoberg et al., 2008). In contrast, DAergic
metabolic levels were inversely associated with testosterone in low
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MAOA activity carriers (Sjoberg et al., 2008). Although both low-
activityMAOA variants and testosterone have been independently
shown to affect aggression, it remains unclear how this genotype
may predispose individuals to higher androgen synthesis and how
these two properties may interact to influence aggression. It is
worth noting that males have a markedly higher frequency of low
MAO A activity variants than females (Sjoberg et al., 2008).
Although the mechanism is unclear, females harboring the
high-activity MAOA variant display higher baseline cortisol levels
than males with the same polymorphism than females carrying
low-activity alleles (Jabbi et al., 2007). Furthermore, both females
and males harboring low-activity MAOA variants exhibited a sex-
ually dimorphic increase in stress response, which was dependent
on COMT genotype (Bouma et al., 2012). In particular, male
carriers of the Met/Met COMT allele displayed a significantly
higher cortisol response to stress than both females with the same
allele and males with other genotypes. Conversely, females car-
rying the Val/Val COMT allele in combination with low-activity
MAOA variants showed higher stress responses than their male
and female counterparts.
Although no common polymorphisms have been reported
in the gene’s coding region, MAOB allelic variants may possess
different enzymatic activities (Balciuniene et al., 2002; Costa-
Mallen et al., 2005). Indeed, several groups have reported the
association of polymorphic variants of MAOB gene with several
neuropsychiatric disorders characterized by DAergic dysfunction.
In particular, MAOB allelic variations have been associated with
bipolar disorder (Lin et al., 2000) and higher schizophrenia sus-
ceptibility (Hovatta et al., 1999; Gasso et al., 2008; Carrera et al.,
2009; Piton et al., 2011); these results, however, have been not
been consistently replicated (Coron et al., 1996; Sobell et al., 1997;
Matsumoto et al., 2004; Bergen et al., 2009).
A direct implication of MAOB in schizophrenia is supported
by several studies (Coron et al., 1996; Bergen et al., 2009; Carrera
et al., 2009; Piton et al., 2011; Wei et al., 2011; Sun et al.,
2012a) and may be reflective of the greater contribution of
this enzyme to the metabolism of DA in humans. In particu-
lar (see Table 2), numerous articles have recently reported that
different MAOB variants may predispose to schizophrenia in
women (Gasso et al., 2008; Wei et al., 2011) or in men (Wei
and Hemmings, 1999). In addition, other studies highlighted that
MAOB variants may moderate several symptomatic aspects of
schizophrenia, including flat affect (Camarena et al., 2012) or
paranoid manifestations (Sun et al., 2012a). Although little is cur-
rently known on the potential interaction of sex hormones with
MAOB, females have been reported to display significantly higher
MAO B activity in platelets in comparison with males (Snell et al.,
2002).
A plethora of studies has shown that sex hormones differen-
tially affect MAO activity and expression in specific brain regions.
Androgens increase MAO transcription in the substantia nigra
(Ou et al., 2006; Purves-Tyson et al., 2012) and in the striatum
(Thiblin et al., 1999). Chronic administration of anabolic andro-
genic steroids, however, reduces MAO activity in the caudate and
amygdala, as well as DA metabolites in the nucleus accumbens
shell (Birgner et al., 2008). Similarly, gonadectomy also increases
MAO A activity in the PFC (Meyers et al., 2010), suggesting
that acute treatment with androgens may enhance MAO activ-
ity, while chronic treatment exerts the opposite effect. In contrast
to androgens, estrogen administration to neonatal, but not adult
males elicits an increase in hypothalamic MAO activities (Vaccari
et al., 1981). In females, estradiol reduces MAO A activity in the
hypothalamus and amygdala (Luine et al., 1975; Ma et al., 1993;
Gundlah et al., 2002).
OTHER DAergic TARGETS
The current evidence on the implication of the other DAergic tar-
gets in G×S interactions is scant and mostly limited to DAergic
receptors. Interestingly, several studies have shown that polymor-
phic variants of the genes encoding D1,D2, and D4 receptors are
linked to different responses to antipsychotic medications in a
gender-sensitive fashion. For example, variants of theDRD2 gene,
which codes for the D2 receptor, may predispose females to a
greater prolactin increase in response to antipsychotics (Mihara
et al., 2000, 2001); however, this difference may not be depen-
dent on an actual G×S interaction, but rather on the higher
baseline levels of prolactin in females (Yasui-Furukori et al.,
2008). Variants of the DRD1 and DRD4 genes (coding for D1
and D4 receptors) may also predispose to different responses to
antipsychotic treatment (including side effects) (Hwu et al., 1998;
Potkin et al., 2003; Hwang et al., 2007; Popp et al., 2009). Only
few studies have pointed to a direct role of these genes in spe-
cific symptomatic aspects. Different variants of the DRD2 gene
may be associated with higher perseverative responses in female
schizophrenia patients (Rybakowski et al., 2005), while VNTR
variants of the DRD4 gene may predict for differences in age of
onset in female patients (Goncalves et al., 2012). Notably, the
DRD1 gene has been recently found to establish an epistatic inter-
action with the COMT gene, which predicts schizophrenia risk
in males, presumably due to the functional association of D1
receptors and COMT in the PFC (Hoenicka et al., 2010).
Independent investigations have reported that different vari-
ants of the DRD3 gene may be associated with schizophrenia
predisposition in males (Asherson et al., 1996; Griffon et al.,
1996) and females (Aksenova et al., 2004; Godlewska et al., 2010).
Interestingly, preliminary results in our animal models suggest
that the behavioral responses elicited by agonists of D3, but not
D2 receptors, may be under control of neurosteroids with respect
to the regulation of sensorimotor gating (Frau et al., submitted).
Future work is warranted to establish the nature of this intriguing
neurobiological finding.
CONCLUDING REMARKS
As mentioned above, the attempts to identify a genetic basis of
schizophrenia have revealed a picture of extreme complexity and
high heterogeneity of heritable bases. This view has gradually
replaced our “genome-centric” perspective with a broader frame-
work, in which genetic vulnerability is a piece of a much greater
mosaic, consisting of complex interactions with environmental
factors. In this perspective, sex hormones may also play a signifi-
cant role in shaping the course of schizophrenia and modifying
the developmental trajectory of the neurobiological alterations
of DA and other neurotransmitter systems underpinning this
disorder.
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Table 2 | List of major studies implicating the interaction between MAO polymorphic variants and sex in schizophrenia and related symptoms.
Study aim Polymorphisms (SNP
if applicable)
Total subjects Male: female
ratio
Finding References
Role of MAO A and B
polymorphisms in negative and
positive schizophrenia
symptoms
MAOA: 3-repeat and
4-repeat uVNTR
MAOB: rs1799863 and
rs1137070
468 (344
patients and 124
controls)
209:135 patients
60:64 controls
Higher affective flattening in
female schizophrenic
patients homozygous for
MAOA 4-repeat uVNTR and
MAOB/rs1799836 (GG)
Camarena et al.,
2012
Role of MAO A gene
polymorphisms in paranoid
schizophrenia in a Chinese
population
MAOA 3-repeat and
4-repeat uVNTR and 41
SNPs
1122 (555
patients and 567
controls)
284:271 patients
308:259 controls
VNTR 3-repeat-rs6323,
VNTR 3-repeat-rs1137070
and VNTR
3-repeat-rs6323-rs1137070
haplotypes associated with
paranoid schizophrenia in
females
Sun et al.,
2012a; Sumner
and Fink, 1993
Association of MAO A/B genes
and schizophrenia in a Chinese
population
MAOA: rs6323 MAOB:
rs1799836
1073 (537
patients and 536
controls)
294:243 patients
284:252 controls
MAO A rs6323 and MAO B
rs1799836 haplotype
associated with
schizophrenia in females
Wei et al., 2011
Association between
antipsychotic-induced restless
legs syndrome and MAO
polymorphisms in
schizophrenia
MAO A: 3-repeat and
4-repeat uVNTR MAO
B: A644G SNP
190 patients 106:84 patients Males patients with MAO A
3-repeat uVNTR and MAO
B A644 genotype has
higher association with
antipsychotic-induced
restless leg syndrome
Kang et al., 2010
Association of MAO gene
microsatellites with
schizophrenia
MAO A: (AC)n repeats
MAO B: (TG)n repeats
89 nuclear
families with
schizophrenic
offspring
Not indicated Families of male
schizophrenia patients had
higher frequency of
transmitted MAO B (TG)24
repeats
Wei and
Hammings, 1998
Association of MAO A gene
variants and schizophrenia in a
Chinese population
MAO A uVNTR 3-repeat
and 4 repeat and
-941G/T and -1460C/T
restriction fragment
length polymorphisms
355 (234
patients and 121
controls)
156:78 patients
76:45 controls
Haplotype association of
schizophrenia with 3-repeat
uVNTR and -941T allele in
males
Qiu et al., 2009
MAO platelet activity
relationship to auditory
hallucinations and paranoia in
schizophrenics
MAO platelet activity
(MAO B)
237 (101 patients
and 136
controls)
64:37 patients
65:71 controls
Decreased platelet MAO
activity associated with
paranoid subtype and
presence of auditory
hallucinations in male
schizophrenia patients
Meltzer and
Zureick, 1987
The findings summarized in this review indicate that, although
the role of G×S interactions in schizophrenia is still inconclusive,
sex hormones might affect brain substrates through a multilay-
ered set of mechanisms, which appear to have a particular impact
on the catabolic apparatus of DA.
The diagnostic definition of schizophrenia (as based on the
DSM-IV and DSM-5) is only related to symptomatic descrip-
tors, rather than biomarkers and quantitative endophenotypes.
This scenario raises the possibility that this disorder may actually
correspond to an array of diverse clinical conditions which share
a common “final pathway” accounting for the pathognomonic
manifestations of schizophrenia. Accordingly, a greater under-
standing of the role of DA neurotransmission in schizophrenia
may have important repercussions also with respect to a better
nosographic classification of this disorder.
The integration of preclinical research with neuroimaging and
genetic studies will play a critical role in enabling us to identify
central neurobiological networks that underpin gender-specific
neurobehavioral endophenotypes of schizophrenia. Additionally,
the contribution of these studies and a greater understanding
of sex-dependent epigenetic mechanisms of transcriptional reg-
ulation will be fundamental to qualify premorbid signs and
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symptoms, and chart the developmental trajectory of psychosis
in males and females.
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